The US Preventive Services Task Force has issued a grade A recommendation that clinicians offer pre-exposure prophylaxis (PrEP) to people at high risk of acquiring HIV. Currently, many fewer individuals receive PrEP than those who would benefit from it; whether PrEP can have a real impact on reducing the global burden of HIV is yet to be determined.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Owens, D. K. et al. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force Recommendation Statement. JAMA 321, 2203–2213 (2019).
Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS data 2018. UNAIDS https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf (2018).
Tsai, C. C. et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270, 1197–1199 (1995).
Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587–2599 (2010).
Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399–410 (2012).
Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 update: a clinical practice guideline. CDC https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf (2017).
World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. WHO https://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/ (2015).
Grulich, A. E. et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV 5, e629–e637 (2018).
Fauci, A. S. et al. Ending the HIV epidemic: a plan for the United States. JAMA 321, 844–845 (2019).
Riddell, J. T., Amico, K. R. & Mayer, K. H. HIV preexposure prophylaxis: a review. JAMA 319, 1261–1268 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.M.B. has led studies of pre-exposure prophylaxis with funding from the US National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), United States Agency for International Development (USAID) and the Bill & Melinda Gates Foundation and has served on advisory boards for Gilead Sciences and Merck. Funding to support the present work is from NIH grants R01 MH095587 and P30 AI027757.
Additional information
Related links
PrEPWatch: http://prepwatch.org
Prevention access campaign: https://www.preventionaccess.org/
Rights and permissions
About this article
Cite this article
Baeten, J.M. PrEP for HIV: grade A for evidence but pending for impact. Nat Rev Urol 16, 570–571 (2019). https://doi.org/10.1038/s41585-019-0219-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0219-x
